DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20214490

An institutional evaluation of radiotherapy with concurrent and adjuvant temozolomide exclusively in grade III gliomas

Naga Chandra Sekhar Darisi, V. L. Anusha Konakalla, Venkata Pradeep Babu Koyyala

Abstract


Background: Gliomas are the most common tumors that develop from glial cells in the brain. As per WHO classification, grade III (high-grade) gliomas are usually treated by surgery followed by radiotherapy. Concurrent and adjuvant chemotherapy with temozolomide (TMZ) is showing new hope in the management.

Methods: Prospective study was conducted in 20 WHO grade III glioma patients at GSL medical college and general hospital for a period of 2 years (August 2019 to July 2021) to evaluate the role of concurrent and adjuvant TMZ with radiation in the treatment of grade III gliomas. The primary objectives of the study were to determine toxicity and response rates in our set of patients. The secondary objectives were to determine progression-free survival and overall survival.

Results: Majority were males (80%) in the age group of 30 to 49 (75%). 40% of gliomas were in the temporal lobe. Headache was the most presenting symptom (60%) followed by seizures (35%).70 to 80 Karnofsky performance status/ KPS score was seen in 70% of cases. None of the patients in the study had grade 3 or 4 toxicities. 40% had a complete response according to MacDonald’s criteria. At a median follow-up of 10 months, 25% of patients had disease progression and 1yr overall survival was 95%.

Conclusions: TMZ combined with radiation was well tolerated in our set of patients with grade III gliomas without any significant toxicity.


Keywords


Grade III glioma, TMZ, Radiotherapy

Full Text:

PDF

References


GBD 2016 Brain and Other CNS Cancer Collaborators. Global, regional, and national burden of the brain and other CNS cancer, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(4):376-93.

Wesseling, P, and D Capper. WHO 2016 Classification of gliomas. Neuropathol Appl Neurobiol. 2018;44(2):139-50.

Dong X, Noorbakhsh A, Hirshman BR, Zhou T, Tang JA, Chang DC et al. Survival trends of grade I, II, and III astrocytoma patients and associated clinical practice patterns between 1999 and 2010: A SEER-based analysis. Neurooncol Pract. 2016;3(1):29-38.

Altwairgi AK, Raja S, Manzoor M, Aldandan S, Alsaeed E, Balbaid A et al. Management and treatment recommendations for World Health Organization Grade III and IV gliomas. Int J Health Sci (Qassim). 2017;11(3):54-62.

Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomized phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459-66.

Stewart LA. Chemotherapy in adult high-grade glioma: A systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet. 2002;359:1011-8.

Yung WK, Prados MD, Yaya-tur R, Rosenfeld SS, Brada, Friedman HS et al. Multicenter phase II trial of Temozolomide With anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. J Clin Oncol. 2015;17:2762-71.

Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8(7):1277-80.

Ostrom QT, Gittleman H, Stetson L, Virk SM, Barnholtz-Sloan JS. Epidemiology of gliomas. Cancer treat Res .2015;163:1-14.

Tian M, Ma W, Chen Y, Yu Y, Zhu D, Shi J. Impact of gender on the survival of patients with glioblastoma. Biosci Rep. 2018;38(6):BSR20180752.

McKinley BP, Michalek AM, Fenstermaker RA, Plunkett RJ. The impact of age and sex on the incidence of glial tumors in New York state from 1976 to 1995. J Neurosurg. 2000;93(6):932-9.

Larjavaara S, Mäntylä R, Salminen T, Haapasalo H, Raitanen J, Jääskeläinen J et al. Incidence of gliomas by anatomic location. Neuro Oncol. 2007;9(3):319-25.

Niewald M, Berdel C, Fleckenstein J, Licht N, Ketter R, Rübe C. Toxicity after radiochemotherapy for glioblastoma using temozolomide--a retrospective evaluation. Radiat Oncol. 2011;6:141.

Jalali R, Raut N, Arora B, Gupta T, Dutta D, Munshi A et al. Prospective evaluation of radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma. Int J Radiat Oncol Biol Phys. 2010;77(1):113-8.

Young-Hoon K, Park CK, Cho WH, Kim IA, Moon S, Choe G et al. Temozolomide during and after radiation therapy for WHO grade III gliomas: preliminary report of a prospective multicenter study. J Neurooncol. 2011;103(3):503-12.

Hwang K, Kim TM, Park CK, Chang JH, Jung TY, Kim JH et al. Concurrent and Adjuvant Temozolomide for Newly Diagnosed Grade III Gliomas without 1p/19q Co-deletion: A Randomized, Open-Label, Phase 2 Study (KNOG-1101 Study). Cancer Res Treat. 2020;52(2):505-15.

Van Den Bent MJ, Brandes AA, Taphoorn MJ, Kros JM, Kouwenhoven MC, Delattre JY et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol. 2013;31:344-50.

Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol. 2013;31:337-43.

Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol. 2009;27:5874-80.

van den Bent MJ, Baumert B, Erridge SC, Vogelbaum MA, Nowak AK, Sanson M, et al. Interim results from the CATNON trial (EORTC STUDY 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. Lancet. 2017;390:1645-53.